Citius Pharmaceuticals Inc. (NASDAQ:CTXR) and Cerus Corporation (NASDAQ:CERS) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Citius Pharmaceuticals Inc.||N/A||0.00||13.17M||-1.06||0.00|
We can see in table 1 the earnings per share, gross revenue and valuation of Citius Pharmaceuticals Inc. and Cerus Corporation.
Table 2 represents Citius Pharmaceuticals Inc. (NASDAQ:CTXR) and Cerus Corporation (NASDAQ:CERS)’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Citius Pharmaceuticals Inc.||0.00%||-54.2%||-48.3%|
Volatility & Risk
A 1.19 beta indicates that Citius Pharmaceuticals Inc. is 19.00% more volatile compared to Standard & Poor’s 500. Competitively, Cerus Corporation is 45.00% more volatile than Standard & Poor’s 500, because of the 1.45 beta.
Citius Pharmaceuticals Inc.’s Current Ratio is 1.8 while its Quick Ratio is 1.8. On the competitive side is, Cerus Corporation which has a 3.5 Current Ratio and a 3.2 Quick Ratio. Cerus Corporation is better positioned to pay off short and long-term obligations compared to Citius Pharmaceuticals Inc.
In next table is given Citius Pharmaceuticals Inc. and Cerus Corporation’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Citius Pharmaceuticals Inc.||0||0||0||0.00|
On the other hand, Cerus Corporation’s potential upside is 48.27% and its consensus target price is $9.
Insider & Institutional Ownership
Roughly 5% of Citius Pharmaceuticals Inc. shares are owned by institutional investors while 68.4% of Cerus Corporation are owned by institutional investors. Insiders owned roughly 44.4% of Citius Pharmaceuticals Inc.’s shares. Competitively, 0.5% are Cerus Corporation’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Citius Pharmaceuticals Inc.||6.03%||28.13%||3.36%||-16.33%||-64.76%||18.27%|
For the past year Citius Pharmaceuticals Inc. has weaker performance than Cerus Corporation
Cerus Corporation beats on 7 of the 10 factors Citius Pharmaceuticals Inc.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment of catheter related bloodstream infections; and Hydrocortisone-Lidocaine Cream for the treatment of mild to moderate hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was founded in 1991 and is headquartered in Concord, California.